| Amy Lachewitz, MD | |
|
833 Chestnut St Ste 301, Philadelphia, PA 19107-4405 | |
| (215) 955-7190 | |
| (215) 955-8600 |
| Full Name | Amy Lachewitz |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 833 Chestnut St Ste 301, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023463973 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD468002 (Pennsylvania) | Primary |
| 207P00000X | Emergency Medicine | MD468002 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Jefferson University Hospital | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Associates In Healthcare, Inc | 6406755651 | 264 |
News Archive
Patients in a vegetative state are awake, breathe on their own, and seem to go in and out of sleep. But they do not respond to what is happening around them and exhibit no signs of conscious awareness. With communication impossible, friends and family are left wondering if the patients even know they are there.
Canada's leading health care associations are calling on federal and provincial/territorial health ministers to tackle a number of pressing issues at the ministers' annual meeting, taking place in Winnipeg September 17.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional genetic testing.
In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient's vital signs. GE's vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.
› Verified 3 days ago
| Entity Name | Jefferson University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326093675 PECOS PAC ID: 7911819180 Enrollment ID: O20040225000232 |
News Archive
Patients in a vegetative state are awake, breathe on their own, and seem to go in and out of sleep. But they do not respond to what is happening around them and exhibit no signs of conscious awareness. With communication impossible, friends and family are left wondering if the patients even know they are there.
Canada's leading health care associations are calling on federal and provincial/territorial health ministers to tackle a number of pressing issues at the ministers' annual meeting, taking place in Winnipeg September 17.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional genetic testing.
In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient's vital signs. GE's vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.
› Verified 3 days ago
| Entity Name | Methodist Associates In Healthcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053355131 PECOS PAC ID: 6406755651 Enrollment ID: O20040402000835 |
News Archive
Patients in a vegetative state are awake, breathe on their own, and seem to go in and out of sleep. But they do not respond to what is happening around them and exhibit no signs of conscious awareness. With communication impossible, friends and family are left wondering if the patients even know they are there.
Canada's leading health care associations are calling on federal and provincial/territorial health ministers to tackle a number of pressing issues at the ministers' annual meeting, taking place in Winnipeg September 17.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional genetic testing.
In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient's vital signs. GE's vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.
› Verified 3 days ago
| Entity Name | Jefferson Acute Care Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730571324 PECOS PAC ID: 7810215613 Enrollment ID: O20150407001063 |
News Archive
Patients in a vegetative state are awake, breathe on their own, and seem to go in and out of sleep. But they do not respond to what is happening around them and exhibit no signs of conscious awareness. With communication impossible, friends and family are left wondering if the patients even know they are there.
Canada's leading health care associations are calling on federal and provincial/territorial health ministers to tackle a number of pressing issues at the ministers' annual meeting, taking place in Winnipeg September 17.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional genetic testing.
In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient's vital signs. GE's vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Lachewitz, MD 700 Walnut St, Philadelphia, PA 19106-3505 Ph: (215) 503-7300 | Amy Lachewitz, MD 833 Chestnut St Ste 301, Philadelphia, PA 19107-4405 Ph: (215) 955-7190 |
News Archive
Patients in a vegetative state are awake, breathe on their own, and seem to go in and out of sleep. But they do not respond to what is happening around them and exhibit no signs of conscious awareness. With communication impossible, friends and family are left wondering if the patients even know they are there.
Canada's leading health care associations are calling on federal and provincial/territorial health ministers to tackle a number of pressing issues at the ministers' annual meeting, taking place in Winnipeg September 17.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease.
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional genetic testing.
In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient's vital signs. GE's vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.
› Verified 3 days ago
Srikar Vegesna, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2118 Cottman Ave, Philadelphia, PA 19149 Phone: 215-342-3020 Fax: 215-342-3653 | |
Chelsea Tiffany Salas-tam, Family Medicine Medicare: Medicare Enrolled Practice Location: 833 Chestnut St Ste 301, Philadelphia, PA 19107 Phone: 215-955-7190 | |
Meng-chao Lee, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7500 Central Ave Ste 104, Philadelphia, PA 19111 Phone: 215-742-0712 Fax: 215-742-5218 | |
Carol Bowes-lawlor, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 33 E Chestnut Hill Ave, Philadelphia, PA 19118 Phone: 215-753-9080 Fax: 215-753-8830 | |
Dr. Seung Hee Hong, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 150, Philadelphia, PA 19134 Phone: 215-926-3535 Fax: 215-926-3536 | |
Dr. Denise Hamilton Christian, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 251 E Bringhurst St, Philadelphia, PA 19144 Phone: 215-844-1020 Fax: 215-844-8147 | |
Mara Leyzin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8025 Castor Ave, Philadelphia, PA 19152 Phone: 215-745-9900 Fax: 215-745-9902 |